Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1121 participants
OBSERVATIONAL
2008-03-31
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
e-BioMatrix PostMarket Registry
NCT01289002
e-BioMatrix Canada Registry
NCT01915628
e-BioMatrix 6 Month DAPT France
NCT03461484
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
NCT02871622
BioFreedom French Registry
NCT03745066
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients that need a treatment with a BioMatrix™ drug-eluting stent
3. Presence of one or more coronary artery stenoses in a native coronary artery or a saphenous bypass graft from 2.25 to 4.0 mm in diameter that can be covered with one or multiple stents
4. No limitation on the number of treated lesions, and vessels, and lesion length
Exclusion Criteria
2. Patients needing additional stent NOT of the BioMatrix™ type
3. Patients receiving next to the BioMatrix™ stent also other coronary vascular interventions, for example dilation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biosensors Europe SA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philip Urban, MD
Role: PRINCIPAL_INVESTIGATOR
Hôpital de La Tour
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arrixaca University Hospital
Murcia, , Spain
Inselspital
Bern, , Switzerland
Hôpital Cantonal de Fribourg
Fribourg, , Switzerland
Hôpitaux Universitaires de Genève
Geneva, , Switzerland
Cardiocentro Ticino
Lugano, , Switzerland
Hôpital de La Tour
Meyrin, , Switzerland
Triemli Hospital
Zurich, , Switzerland
Brighton-Sussex University Hospitals
Brighton, , United Kingdom
Manchester Heart Center
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07EU01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.